Skip to main content
. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173

Figure 3.

Figure 3

Event-free survival (EFS) according to patient group. The Kaplan-Meier plot of the imatinib arm of the International Randomized Study of Interferon and STI571 (IRIS) trial for frontline patients with chronic myeloid leukemia is also shown, to illustrate that biphasic responders do approximately as well as patients receiving frontline imatinib treatment.